Using a known human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI), 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole (TBZ NSC 625487) as the lead structure for drug design, a series of novel 1H,3H-thiazolo[3,4-a]benzimidazole derivatives substituted on the benzene-fused ring was prepared. Their in vitro anti-HIV-1 activity, as well as their inhibitory effects on the viral reverse transcriptase, were evaluated. The structure-activity relationships for these compounds are described and the results suggest that the apolar binding pocket of RT, into which the NNRTIs must fit, can accommodate only groups with a limited size and shape.
The rapid global spread of AIDS has prompted numerous efforts to develop therapeutic agents, in particular against human immunodeficiency virus type 1 (HIV-1), that have served as important tools to investigate different aspects of viral replication in HIV-infected individuals.
The largest number of these drugs target the viral reverse transcriptase (RT), which is an essential enzyme that operates in the early phase of the replication cycle to generate proviral DNA from the RNA that is packaged within the virus (Le Grice, 1993; Tantillo et al., 1994) .
RT inhibitors fall into two general classes: (1) nucleoside analogues that, after cellular enzyme activation, act as DNA chain terminators during the RT polymerization reaction; and (2) non-nucleoside RT inhibitors (NNRTIs), which are derived from diverse chemical classes sharing the ability to inhibit the enzyme by binding at a common site on the RT, which is proximal to the polymerase active site (Esnouf et al., 1995; Spence et al., 1995) .
In previous publications we reported a series of 1-aryl substituted 1H,3H-thiazolo[3,4-a]benzimidazole derivatives (TBZs) exhibiting anti-HIV-1 activity (Chimirri et al., 1991a,b) . Their mechanism of action was elucidated and found to be allosteric inhibition of viral reverse transcriptase with subsequent retardation of viral replication (Schultz et al., 1992) . The lead compound in the thiazolobenzimida-zole class of RT inhibitors was 1-(2,6-difluorophenyl)-1H, 3H-thiazolo[3,4-a] benzimidazole (TBZ NSC 625487; Figure 1 ). This compound proved to be a highly potent inhibitor of HIV-1-induced cell killing and viral replication in a variety of human cell lines and was active against biologically diverse strains of HIV-1, including the AZT-resistant strain G910-6, both as racemate (Buckheit et al., 1993) and single enantiomers (Chimirri et al., 1997a) .
Analogously to other NNRTIs, the biological activity of TBZs seems to be associated with the possibility of assuming a 'butterfly-like' shape that allows the interactions between the aromatic groups of TBZs and amino acid residues in the non-nucleoside inhibitor binding pocket (NNIBP) of RT (Chimirri et al., 1997a; 1998) . Furthermore, comparative molecular field analysis (CoMFA) and docking experiments (Barreca ML, Chimirri A, Carotti A, Carrieri A, Monforte AM, Pellegrini Calace M, Rao A, personal communication) have suggested that a possible approach in designing more effective inhibitors might be to devise compounds bulkier in the favourable steric zone to better fill the available space in the NNIBP.
To confirm this hypothesis and to better define which structural elements are necessary for the inhibition of the RT enzyme, the synthesis and anti-HIV activity, as well as the inhibitory effects on HIV-1 RT, of a series of 1H,3H-Antiviral Chemistry & Chemotherapy 10:211-217
Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors
Introduction thiazolo[3,4-a]benzimidazoles (1-2, 3a-16a and 3b-16b) suitably substituted at different positions of the benzenefused ring are herein reported. In all compounds the 2,6dihalo substituted phenyl ring at C-1 was retained as a suitable moiety to have active NNRTIs (Chimirri et al., 1996 (Chimirri et al., , 1997b . The resulting modulation of the anti-HIV activity and structure-activity relationships (SAR) of a variety of substitutions are also described.
Materials and Methods: Chemistry
Melting points were determined on a Kofler hot stage apparatus and are uncorrected. Elemental analyses were carried out on a C Erba Model 1106 Elemental Analyzer (C, H, N) and the results were within ±0.4% of the theoretical values. Merck silica gel 60 F 254 plates were used for TLC; column chromatography was performed on Merck silica gel 60 (70-230 mesh). 1 H-and 13 C-NMR spectra were measured with a Varian (Palo Alto, Calif., USA) Gemini 300 spectrometer in CDCl 3 with TMS as internal standard: chemical shifts are expressed in δ (p.p.m.) and coupling constants ( J) in hertz. Direct and long-range heteronuclear chemical shifts correlation experiments (HET-COR and LR-HETCOR) were carried out using the standard software package.
Procedure for 1-aryl-1H,3H-thiazolo[3,4-a] benzimidazoles 1-2, 3a-16a and 3b-16b
To a stirred solution of the substituted 1,2-diaminobenzene (8 mmol) in dry benzene (50 ml), 2-mercaptoacetic acid (16 mmol) and the appropriate aromatic aldehyde (8 mmol) were added. The reaction mixture was refluxed for 48 h and then neutralized with a solution of sodium hydrogen carbonate. After removal of the solvent under reduced pressure, the oily residue was treated with diethyl ether to afford, as solid compounds, derivatives 1 or 2, or the mixture of the two isomers a and b, which were separated by silica gel column chromatography eluting with cyclohexane:ethyl acetate 6:4. Derivatives a were eluted before the corresponding isomers b. All compounds were recrystallized from ethanol. 
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Materials and Methods: Virology
In vitro anti-HIV assay
The antiviral experiments using MT-4 cell cultures and HIV-1 (III B ) and HIV-2 (ROD) were performed following procedures that have been previously described (Pauwels et al., 1988; Witvrouw et al., 1991) .
RT assay
The RT assay using recombinant HIV-1 RT was performed as described previously (Balzarini et al., 1992) .
Results

Chemistry
The synthesis of 5-, 6-, 7-or 8-substituted 1-aryl-1H,3Hthiazolo[3,4-a] benzimidazoles 1-2, 3a-16a and 3b-16b reported here, was accomplished according to a procedure that has already been used in our laboratory (Chimirri et al., 1991b) , by reacting a 1,2-diaminobenzene 3-, 4-or 4,5substituted with 2-mercaptoacetic acid and an aromatic aldehyde, as shown in Figure 2 . When the aromatic amine employed is 3-or 4-substituted, the reaction affords an approximately 1:1 mixture of isomers a and b, characterized by a different position of the substituent on the benzene-fused ring. The a and b isomers were separated by column chromatography. Their structures were assigned on the basis of 1 H-and 13 C-NMR spectroscopy and in particular by means of HETCOR and LR-HETCOR. The LR-HETCOR experiments were obtained with a pulse sequence optimized to observe typical three-bond proton to carbon couplings. The key entry point is afforded by the long-range correlations of carbons C-4a and C-8a to the protons of the benzene-fused ring. For example, in derivative 8a, the signal of C-8a is longrange correlated to three proton resonances (H-1, H-5 and H-7), whereas in isomer 8b the same carbon has longrange correlations to protons H-1 and H-5. Analogously, C-4a exhibits long-range correlations to H-8 in the 6-substituted derivative and to H-6 and H-8 in the corresponding 7-substituted isomer.
In vitro anti-HIV activity
The antiviral activities of compounds 1-2, 3a-16a and 3b-16b were evaluated in MT-4 cells acutely infected with HIV-1 (III B ) or HIV-2 (ROD) and compared with TBZ (NSC 625487). The results are presented in Table 1 . Derivatives 3a, 3b, 4a, 8a, 8b and 9a were found to inhibit HIV-1 (III B ) replication at subtoxic concentrations, 4a being the most active and resulting in a selectivity index of >208. None of the compounds inhibited the replication of HIV-2 (ROD) in MT-4 cells.
Anti-HIV-1 RT activity
Derivatives 3a and 3b were also evaluated for their inhibitory effects on HIV-1 RT and compared with TBZ (NSC 625487) ( Table 2) . These compounds inhibited the RT enzymatic activity by 50%, (IC 50 ) at 24.1 and 13.4 µM, respectively. This means that they showed a comparable activity with respect to TBZ.
Discussion
As mentioned in the introduction, in the course of our previous research we found that 1H,3H-thiazolo[3,4-a]benz-imidazole derivatives are specific HIV-1 RT inhibitors. We began our study of the anti-HIV SAR around the thiazoline ring of TBZ by evaluating variations solely at the C-1 site and identified the 2,6-dihalo substituted phenyl as a structural requirement necessary for activity. In fact, the features that seem important for NNRTI binding include the presence of two planar π electronic systems having the ability to adopt a "butterfly-like" conformation and the presence of a hydrogen bond acceptor.
Recently we derived an informative and statistically significant CoMFA model for a wide series of NNRTIs (Barreca ML, Chimirri A, Carotti A, Carrieri A, Monforte AM, Pellegrini Calace M, Rao A, personal communication). The main molecular determinants responsible for high inhibitory activity were found to be a suitable location in space of lipophilic and electronic groups as well as the butterfly-like shape. In particular, the above-mentioned study suggested the possibility to design more efficient inhibitors synthesizing bulkier TBZ analogues able to better fill the available space in the NNIBP. On this basis, the synthesis and the evaluation of the anti-HIV activity of 1H, 3H-naphtho[2′,3′:4,5] imidazo [1,2-c] thiazoles was carried out (Chimirri et al., 1997b) . Although the spatial orientation of naphthoimidazothiazole showed a hydrophobic butterfly-like conformation, the compounds obtained lacked substantial activity, thus suggesting that the apolar pocket of RT could not well accommodate the large size of naphthyl moiety.
Following these results and in order to better determine the optimal substitution pattern able to improve the inhibitory potency of TBZs toward HIV-1 RT and HIV-1 replication, the SAR of a series of new TBZ derivatives was examined by varying the benzene-fused ring substitutions. The ability of the structural changes introduced in the benzimidazole system to influence the anti-HIV activity is shown in Table 1 and discussed below.
In this series of compounds the inhibitory potency and toxicity are dependent upon the position and nature of the substituent in the benzene-fused ring. Specifically, small lipophilic substituents such as fluorine or a methyl group are generally preferred, while larger groups result in weakly active or inactive compounds.
It is interesting to note that the most active compound of this new series of TBZs, 4a (EC 50 1.9 µM), with a methyl group at C-5 position is also the least toxic with a selectivity index of >208, higher than other RT inhibitors which are clinically used, such as ddI (Artico, 1996) . The shift of the methyl group to C-8 was accompanied by high toxicity. The 8-methyl substituted 3b was also more toxic than its 5-methyl analogue 3a.
In conclusion, a series of novel thiazolobenzimidazoles, in which we made variations at different positions of the aromatic portion of the tricyclic system, has been prepared. The structural features of the isomers obtained were ascertained by means of HETCOR and LR-HETCOR.
The SAR of this study allowed the discovery of a new interesting RT inhibitor, 5-methyl substituted derivative 4a, which exhibited nearly equipotent activity but less tox- icity with threefold more favourable selectivity index with respect to the original lead compound TBZ (NSC 625487). Substituents at other positions or with bulkier steric hindrance tended to give compounds with decreased activity or high toxicity (Table 1) . Therefore the results of this study too, according to our previous investigations (Chimirri et al., 1996 (Chimirri et al., , 1997b , suggest that NNIBP of RT is able to accommodate only small substituents which must be situated in particular positions of the benzene-fused ring.
The SAR results may help the design of other thiazolobenzimidazoles as better anti-HIV agents.
